scholarly journals Minimal residual disease and log‐reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma

2018 ◽  
Vol 96 (3) ◽  
pp. 195-200 ◽  
Author(s):  
Giovanni Rossi ◽  
Antonietta Pia Falcone ◽  
Maria Marta Minervini ◽  
Giovanni Pio De Cillis ◽  
Chiara De Waure ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Stem Cell Transplant ◽  
Plasma Cells ◽  
Residual Disease ◽  
Autologous Stem Cell Transplant ◽  
Cell Transplant ◽  
Younger Patients ◽  
Log Reduction ◽  
Minimal Residual

Absolute Lymphocyte Count As Predictor of Overall Survival for Patients with Multiple Myeloma Treated with Single Autologous Stem Cell Transplant: Experience of a Single Centre,

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 4121-4121
Author(s):  
Victor H Jimenez-Zepeda ◽  
Donna E. Reece ◽  
Suzanne Trudel ◽  
Christine Chen ◽  
Norman Franke ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Lymphocyte Count ◽  
Research Funding ◽  
Stem Cell Transplant ◽  
Plasma Cells ◽  
Absolute Lymphocyte Count ◽  
Autologous Stem Cell Transplant ◽  
Peripheral Blood Lymphocytes ◽  
Cell Transplant

Abstract Abstract 4121 Post-Autologous stem cell transplant (ASCT) studies have demonstrated that early absolute lymphocyte count (ALC) recovery is associated with prolonged survival in some hematological malignancies. Peripheral blood lymphocytes from Multiple Myeloma (MM) were shown to have direct anti-MM activity by proliferative and cytotoxic responses to autologous and allogeneic myeloma plasma cells Disclosures: Jimenez-Zepeda: J & J: Honoraria. Reece:Bristol, Meyers, Squibb: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; Johnson&Johnson: Research Funding; Merck: Honoraria, Research Funding; Otsuka: Honoraria, Research Funding; Millennium: Research Funding; Amgen: Honoraria. Chen:Celgene Corporation: Consultancy, Honoraria, Research Funding. Kukreti:Celgene: Honoraria.

scholarly journals Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma

2020 ◽  
Vol 34 ◽  
pp. 205873842098025
Author(s):  
Maximilian Johannes Steinhardt ◽  
Xiang Zhou ◽  
Franziska Krummenast ◽  
Katharina Meckel ◽  
Katharina Nickel ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell Transplant ◽  
Residual Disease ◽  
Progression Free Survival ◽  
Autologous Stem Cell Transplant ◽  
Cell Transplant ◽  
Free Survival ◽  
Heavily Pretreated ◽  
Multi Agent ◽  
Minimal Residual

We report on a currently 76-year-old female patient with relapsed/refractory (RR) multiple myeloma (MM) treated at our institution. This patient had received six lines of therapy including tandem autologous stem cell transplant, proteasome inhibitor, immunomodulatory drugs and CD38 antibody MOR202. At the last relapse, she progressed during treatment with pomalidomide and MOR202. In an individualized therapy concept, we started a multi-agent salvage therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and CD38 antibody daratumumab (“Pom-PAD-Dara”), which resulted in a stringent complete remission with minimal residual disease (MRD) negativity after nine cycles. So far, our patient shows a progression free survival of more than 12 months. Our case demonstrates the feasibility of successful CD38 antibody retreatment in a patient with heavily pretreated CD38 antibody resistant MM.

Sign in / Sign up

Export Citation Format

Share Document